Stock Analysis

VBI Vaccines Full Year 2022 Earnings: Revenues Beat Expectations, EPS Lags

Source: Shutterstock

VBI Vaccines (NASDAQ:VBIV) Full Year 2022 Results

Key Financial Results

  • Net loss: US$113.3m (loss widened by 62% from FY 2021).
  • US$0.44 loss per share (further deteriorated from US$0.27 loss in FY 2021).

VBIV Products In Clinical Trials

  • Phase I: 5.
  • Phase II: 1.
NasdaqCM:VBIV Earnings and Revenue History March 15th 2023

All figures shown in the chart above are for the trailing 12 month (TTM) period

VBI Vaccines Revenues Beat Expectations, EPS Falls Short

Revenue exceeded analyst estimates by 8.2%. Earnings per share (EPS) missed analyst estimates by 31%.

Looking ahead, revenue is forecast to grow 59% p.a. on average during the next 3 years, compared to a 14% growth forecast for the Biotechs industry in the US.

Performance of the American Biotechs industry.

The company's shares are down 5.1% from a week ago.

Risk Analysis

It's necessary to consider the ever-present spectre of investment risk. We've identified 5 warning signs with VBI Vaccines (at least 1 which doesn't sit too well with us), and understanding them should be part of your investment process.

What are the risks and opportunities for VBI Vaccines?

VBI Vaccines Inc., a biopharmaceutical company, develops and sells vaccines to treat immuno-oncology and infectious disease.

View Full Analysis


  • Trading at 77.5% below our estimate of its fair value

  • Revenue is forecast to grow 58.23% per year


  • Has less than 1 year of cash runway

  • Does not have a meaningful market cap ($78M)

  • Does not have meaningful revenue ($1M)

  • Volatile share price over the past 3 months

  • Currently unprofitable and not forecast to become profitable over the next 3 years

View all Risks and Rewards

Share Price

Market Cap

1Y Return

View Company Report